Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities (2022 - 2024)

Insight Molecular Diagnostics has disclosed Preferred Stock Liabilities across 3 years of filings, most recently posting $5.3 million for Q1 2024.

• Preferred Stock Liabilities for Q1 2024 came in at $5.3 million, down 3.62% year-over-year; the trailing twelve-month figure through Mar 2024 was $5.3 million (down 3.62% YoY), and the FY2023 annual result was $5.1 million, down 3.32% from the prior year.
• Preferred Stock Liabilities came in at $5.3 million for Q1 2024 at Insight Molecular Diagnostics, up from $5.1 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $5.5 million in Q1 2023 to a low of $4.7 million in Q2 2023.
• The 3-year median for Preferred Stock Liabilities is $5.1 million (2022), against an average of $5.1 million.
• Across the five-year window, Preferred Stock Liabilities slipped 2.66% in 2023 and slipped 3.62% in 2024, its largest moves.
• Insight Molecular Diagnostics' Preferred Stock Liabilities stood at $5.3 million in 2022, then dropped by 3.32% to $5.1 million in 2023, then climbed by 4.02% to $5.3 million in 2024.
• The last three Preferred Stock Liabilities figures came in at $5.3 million (Q1 2024), $5.1 million (Q4 2023), and $4.9 million (Q3 2023), per Business Quant data.